Core One Labs Inc. (CLABF)
OTC PINK OTC PINK Primary Summary
Core One Enters into Loan Agreement with Right Season Investments
VANCOUVER, BC / ACCESSWIRE / July 8, 2024 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has entered into a loan agreement (the "Loan Agreement") with Right Season Investments Corp. ("Right Season") dated June 28, 2024. Under the terms of the Loan Agreement, Right Season has advanced a loan of CDN$300,000 (the "Loan") to the Company.
Core One Labs Inc. (CLABF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Core One Labs Inc. ever had a stock split?
Core One Labs Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gareth Manderson CEO | OTC PINK Exchange | 21871U102 CUSIP |
| CA Country | 192 Employees | - Last Dividend | 6 Sep 2019 Last Split | - IPO Date |
Overview
Core One Labs Inc. stands as a pioneering entity in the realm of psychedelic research and development, focusing its efforts predominantly on crafting psychedelic medicines and integrating them into novel delivery systems as well as psychedelic assisted psychotherapy programs. Initially known as Lifestyle Delivery Systems Inc., the company underwent a name change in September 2019, marking a new phase in its development. Since its inception in 2010, Core One Labs has been committed to expanding the therapeutic potential of psychedelic compounds like psilocybin. With its headquarters located in Vancouver, Canada, the company also ventures into the natural health products sector, provides news dissemination, financing services, and is active in the operation of medical clinics and micro cultivation endeavors.
Products and Services
Core One Labs Inc. extends its operations into various realms, including pioneering research in psychedelic medicines, development of unique delivery systems for these compounds, and running specialized clinics. Below is a detailed exploration of their diverse offerings:
- Psychedelic Medicines and Novel Delivery Systems: Focusing on harnessing the therapeutic potential of psychedelic substances such as psilocybin, Core One Labs innovates in the formulation and development of medicines designed for modern therapeutic use. This involves creating proprietary methods for delivering these compounds effectively and safely to patients.
- Psychedelic Assisted Psychotherapy: Recognizing the significant benefits that psychedelic compounds can offer when combined with psychotherapy, Core One Labs is at the forefront of integrating these substances into therapeutic protocols. Their efforts aim to enhance mental health treatments and provide novel solutions to challenging psychological conditions.
- Natural Health Products: Beyond its focus on psychedelics, Core One Labs also engages in the development and sale of natural health products. This range is designed to complement overall health and well-being, providing consumers with options outside conventional pharmaceuticals.
- News Dissemination Services: To facilitate the spread of pertinent information and advancements within the psychedelic sector, Core One Labs offers news dissemination services. This initiative helps in keeping stakeholders informed about the latest developments in psychedelic research and treatments.
- Financing Services: Aiding in the financial aspect of its operations, Core One Labs provides financing services. This aspect of their business caters to the needs within the psychedelic sector, supporting projects and initiatives that align with their mission.
- Medical Clinics and Micro Cultivation: Core One Labs operates medical clinics, focusing on the application of psychedelics in therapeutic settings. In addition, their involvement in micro cultivation plays a critical role in their research and development processes, ensuring a controlled and sustainable source of psychedelic compounds for studies and medicinal use.
